Aptevo Therapeutics (NASDAQ:APVO) began dosing subjects in its Phase 1 trial for APVO210, a targeted cytokine immunotherapy. APVO210 is a modified form of the cytokine, IL-10, that suppresses inflammation without...
Roth Capital Partners initiated coverage of Aptevo Therapeutics (NASDAQ:APVO) with a “buy” rating and price target of $12. The stock closed at $3.28 on April 11. “In our view, Aptevo remains under the Street’s...